Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 12 entries
Sorted by: Best Match Show Resources per page
Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers.

Cellular oncology : the official journal of the International Society for Cellular Oncology

Melcher R, Zopf W, Hartmann E, Rosenwald A, Hoehn H, Schmid M, Kudlich T, Scheurlen M, Luehrs H.
PMID: 18936529
Cell Oncol. 2008;30(6):507. doi: 10.3233/clo-2008-0452.

No abstract available.

Cite
Melcher R, Zopf W, Hartmann E, et al. Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cell Oncol. 2008;30(6):507doi: 10.3233/clo-2008-0452.
Melcher, R., Zopf, W., Hartmann, E., Rosenwald, A., Hoehn, H., Schmid, M., Kudlich, T., Scheurlen, M., & Luehrs, H. (2008). Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cellular oncology : the official journal of the International Society for Cellular Oncology, 30(6), 507. https://doi.org/10.3233/clo-2008-0452
Melcher, Ralph, et al. "Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers." Cellular oncology : the official journal of the International Society for Cellular Oncology vol. 30,6 (2008): 507. doi: https://doi.org/10.3233/clo-2008-0452
Melcher R, Zopf W, Hartmann E, Rosenwald A, Hoehn H, Schmid M, Kudlich T, Scheurlen M, Luehrs H. Spectral karyotyping and SNP microarray analysis define uniparental disomy (UPD) as a novel mutational mechanism in MSI- and CSI-colorectal cancers. Cell Oncol. 2008;30(6):507. doi: 10.3233/clo-2008-0452. PMID: 18936529; PMCID: PMC4618808.
Copy Download .nbib Format: NLM
Accuracy of emergency department triage using the Emergency Severity Index and independent predictors of under-triage and over-triage in Brazil: a retrospective cohort analysis.

International journal of emergency medicine

Hinson JS, Martinez DA, Schmitz PSK, Toerper M, Radu D, Scheulen J, Stewart de Ramirez SA, Levin S.
PMID: 29335793
Int J Emerg Med. 2018 Jan 15;11(1):3. doi: 10.1186/s12245-017-0161-8.

BACKGROUND: Emergency department (ED) triage is performed to prioritize care for patients with critical and time-sensitive illness. Triage errors create opportunity for increased morbidity and mortality. Here, we sought to measure the frequency of under- and over-triage of patients...

Cite
Hinson JS, Martinez DA, Schmitz PSK, et al. Accuracy of emergency department triage using the Emergency Severity Index and independent predictors of under-triage and over-triage in Brazil: a retrospective cohort analysis. Int J Emerg Med. 2018;11(1):3doi: 10.1186/s12245-017-0161-8.
Hinson, J. S., Martinez, D. A., Schmitz, P. S. K., Toerper, M., Radu, D., Scheulen, J., Stewart de Ramirez, S. A., & Levin, S. (2018). Accuracy of emergency department triage using the Emergency Severity Index and independent predictors of under-triage and over-triage in Brazil: a retrospective cohort analysis. International journal of emergency medicine, 11(1), 3. https://doi.org/10.1186/s12245-017-0161-8
Hinson, Jeremiah S, et al. "Accuracy of emergency department triage using the Emergency Severity Index and independent predictors of under-triage and over-triage in Brazil: a retrospective cohort analysis." International journal of emergency medicine vol. 11,1 (2018): 3. doi: https://doi.org/10.1186/s12245-017-0161-8
Hinson JS, Martinez DA, Schmitz PSK, Toerper M, Radu D, Scheulen J, Stewart de Ramirez SA, Levin S. Accuracy of emergency department triage using the Emergency Severity Index and independent predictors of under-triage and over-triage in Brazil: a retrospective cohort analysis. Int J Emerg Med. 2018 Jan 15;11(1):3. doi: 10.1186/s12245-017-0161-8. PMID: 29335793; PMCID: PMC5768578.
Copy Download .nbib Format: NLM
Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [.

Diagnostics (Basel, Switzerland)

Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M.
PMID: 33671498
Diagnostics (Basel). 2021 Feb 22;11(2). doi: 10.3390/diagnostics11020367.

Loss of Somatostatin Receptor 2 (SSTR2) expression and rising CXC Chemokine Receptor Type 4 (CXCR4) expression are associated with dedifferentiation in neuroendocrine tumors (NET). In NET, CXCR4 expression is associated with enhanced metastatic and invasive potential and worse prognosis...

Cite
Weich A, Rogoll D, Gawlas S, et al. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel). 2021;11(2)doi: 10.3390/diagnostics11020367.
Weich, A., Rogoll, D., Gawlas, S., Mayer, L., Weich, W., Pongracz, J., Kudlich, T., Meining, A., & Scheurlen, M. (2021). Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel, Switzerland), 11(2), . https://doi.org/10.3390/diagnostics11020367
Weich, Alexander, et al. "Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [." Diagnostics (Basel, Switzerland) vol. 11,2 (2021). doi: https://doi.org/10.3390/diagnostics11020367
Weich A, Rogoll D, Gawlas S, Mayer L, Weich W, Pongracz J, Kudlich T, Meining A, Scheurlen M. Wnt/β-Catenin Signaling Regulates CXCR4 Expression and [. Diagnostics (Basel). 2021 Feb 22;11(2). doi: 10.3390/diagnostics11020367. PMID: 33671498; PMCID: PMC7926465.
Copy Download .nbib Format: NLM
Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours.

Comparative clinical pathology

Neumann S, Kaup FJ, Scheulen S.
PMID: 23049492
Comp Clin Path. 2012 Oct;21(5):539-544. doi: 10.1007/s00580-010-1126-y. Epub 2010 Nov 19.

Cytokines are part of pathogenesis in many diseases. Their measurement could be interesting for diagnostic purposes. One cytokine which participates in different inflammatory and neoplastic diseases is interleukin-6 (IL-6). The aim of this study was to investigate the IL-6...

Cite
Neumann S, Kaup FJ, Scheulen S. Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours. Comp Clin Path. 2010;21(5):539-544doi: 10.1007/s00580-010-1126-y.
Neumann, S., Kaup, F. J., & Scheulen, S. (2012). Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours. Comparative clinical pathology, 21(5), 539-544. https://doi.org/10.1007/s00580-010-1126-y
Neumann, Stephan, et al. "Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours." Comparative clinical pathology vol. 21,5 (2012): 539-544. doi: https://doi.org/10.1007/s00580-010-1126-y
Neumann S, Kaup FJ, Scheulen S. Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours. Comp Clin Path. 2012 Oct;21(5):539-544. doi: 10.1007/s00580-010-1126-y. Epub 2010 Nov 19. PMID: 23049492; PMCID: PMC3461252.
Copy Download .nbib Format: NLM
WITHDRAWN: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial.

Archives of gynecology and obstetrics

Rohr UD, Oberhoff C, Markmann S, Gerber B, Scheulen M, Schindler AE.
PMID: 16315026
Arch Gynecol Obstet. 2005 Nov 29; doi: 10.1007/s00404-005-0095-x. Epub 2005 Nov 29.

Ahead of Print article withdrawn by publisher

Cite
Rohr UD, Oberhoff C, Markmann S, et al. WITHDRAWN: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial. Arch Gynecol Obstet. 2005;doi: 10.1007/s00404-005-0095-x.
Rohr, U. D., Oberhoff, C., Markmann, S., Gerber, B., Scheulen, M., & Schindler, A. E. (2005). WITHDRAWN: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial. Archives of gynecology and obstetrics, . https://doi.org/10.1007/s00404-005-0095-x
Rohr, U D, et al. "WITHDRAWN: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial." Archives of gynecology and obstetrics vol. (2005). doi: https://doi.org/10.1007/s00404-005-0095-x
Rohr UD, Oberhoff C, Markmann S, Gerber B, Scheulen M, Schindler AE. WITHDRAWN: The safety of synthetic paclitaxel by intralesional delivery with OncoGeltrade mark into skin breast cancer metastases: method and results of a clinical pilot trial. Arch Gynecol Obstet. 2005 Nov 29; doi: 10.1007/s00404-005-0095-x. Epub 2005 Nov 29. PMID: 16315026.
Copy Download .nbib Format: NLM
Ultrasonic monitoring of zeolite synthesis in real time.

Ultrasonics

Schmachtl M, Kim TJ, Grill W, Herrmann R, Scharf O, Schwieger W, Schertlen R, Stenzel C.
PMID: 10829776
Ultrasonics. 2000 Mar;38(1):809-12. doi: 10.1016/s0041-624x(99)00201-2.

Variations of the phase and amplitude of a transmitted ultrasonic wave package were monitored in real time during the synthesis of zeolite A and zeolite X. For both materials, characteristic changes of the measured attenuation and the sound velocity...

Cite
Schmachtl M, Kim TJ, Grill W, et al. Ultrasonic monitoring of zeolite synthesis in real time. Ultrasonics. 2000;38(1):809-12doi: 10.1016/s0041-624x(99)00201-2.
Schmachtl, M., Kim, T. J., Grill, W., Herrmann, R., Scharf, O., Schwieger, W., Schertlen, R., & Stenzel, C. (2000). Ultrasonic monitoring of zeolite synthesis in real time. Ultrasonics, 38(1), 809-12. https://doi.org/10.1016/s0041-624x(99)00201-2
Schmachtl, et al. "Ultrasonic monitoring of zeolite synthesis in real time." Ultrasonics vol. 38,1 (2000): 809-12. doi: https://doi.org/10.1016/s0041-624x(99)00201-2
Schmachtl M, Kim TJ, Grill W, Herrmann R, Scharf O, Schwieger W, Schertlen R, Stenzel C. Ultrasonic monitoring of zeolite synthesis in real time. Ultrasonics. 2000 Mar;38(1):809-12. doi: 10.1016/s0041-624x(99)00201-2. PMID: 10829776.
Copy Download .nbib Format: NLM
Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence.

The Journal of surgical research

O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S.
PMID: 34520983
J Surg Res. 2021 Sep 11;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11.

BACKGROUND: Colon cancer is a leading cause of cancer-related death. Long non-coding (Lnc) RNAs are critical mediators of tumor biology. H19 is a well-characterized lncRNA involved in p53 regulation and cancer progression. A specific colon cancer data set was...

Cite
O'Brien SJ, Scheurlen K, Rochet A, et al. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021;269:59-68doi: 10.1016/j.jss.2021.08.004.
O'Brien, S. J., Scheurlen, K., Rochet, A., Fiechter, C., Paas, M., Pan, J., Rai, S. N., & Galandiuk, S. (2021). Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. The Journal of surgical research, 26959-68. https://doi.org/10.1016/j.jss.2021.08.004
O'Brien, Stephen J, et al. "Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence." The Journal of surgical research vol. 269 (2021): 59-68. doi: https://doi.org/10.1016/j.jss.2021.08.004
O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021 Sep 11;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11. PMID: 34520983.
Copy Download .nbib Format: NLM
CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.

Diagnostics (Basel, Switzerland)

Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M.
PMID: 33805264
Diagnostics (Basel). 2021 Mar 29;11(4). doi: 10.3390/diagnostics11040605.

We aimed to elucidate the diagnostic potential of the C-X-C motif chemokine receptor 4 (CXCR4)-directed positron emission tomography (PET) tracer

Cite
Weich A, Werner RA, Buck AK, et al. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel). 2021;11(4)doi: 10.3390/diagnostics11040605.
Weich, A., Werner, R. A., Buck, A. K., Hartrampf, P. E., Serfling, S. E., Scheurlen, M., Wester, H. J., Meining, A., Kircher, S., Higuchi, T., Pomper, M. G., Rowe, S. P., Lapa, C., & Kircher, M. (2021). CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel, Switzerland), 11(4), . https://doi.org/10.3390/diagnostics11040605
Weich, Alexander, et al. "CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas." Diagnostics (Basel, Switzerland) vol. 11,4 (2021). doi: https://doi.org/10.3390/diagnostics11040605
Weich A, Werner RA, Buck AK, Hartrampf PE, Serfling SE, Scheurlen M, Wester HJ, Meining A, Kircher S, Higuchi T, Pomper MG, Rowe SP, Lapa C, Kircher M. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas. Diagnostics (Basel). 2021 Mar 29;11(4). doi: 10.3390/diagnostics11040605. PMID: 33805264; PMCID: PMC8067200.
Copy Download .nbib Format: NLM
Characterization and impact of COVID-19-tested and infected patients: Experience of The Johns Hopkins Health System Regional Emergency Departments.

Journal of the American College of Emergency Physicians open

Kelen GD, Swedien D, Hansen J, Klein E, Peterson S, Saheed M, Scheulen J, Mann E.
PMID: 33521776
J Am Coll Emerg Physicians Open. 2020 Dec 08;2(1):e12321. doi: 10.1002/emp2.12321. eCollection 2021 Feb.

BACKGROUND: There is limited understanding of the characteristics and operational burden of persons under investigation (PUIs) and those testing positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presenting to emergency departments (EDs).METHODS: We reviewed all adult ED visits...

Cite
Kelen GD, Swedien D, Hansen J, et al. Characterization and impact of COVID-19-tested and infected patients: Experience of The Johns Hopkins Health System Regional Emergency Departments. J Am Coll Emerg Physicians Open. 2020;2(1):e12321doi: 10.1002/emp2.12321.
Kelen, G. D., Swedien, D., Hansen, J., Klein, E., Peterson, S., Saheed, M., Scheulen, J., & Mann, E. (2021). Characterization and impact of COVID-19-tested and infected patients: Experience of The Johns Hopkins Health System Regional Emergency Departments. Journal of the American College of Emergency Physicians open, 2(1), e12321. https://doi.org/10.1002/emp2.12321
Kelen, Gabor D, et al. "Characterization and impact of COVID-19-tested and infected patients: Experience of The Johns Hopkins Health System Regional Emergency Departments." Journal of the American College of Emergency Physicians open vol. 2,1 (2021): e12321. doi: https://doi.org/10.1002/emp2.12321
Kelen GD, Swedien D, Hansen J, Klein E, Peterson S, Saheed M, Scheulen J, Mann E. Characterization and impact of COVID-19-tested and infected patients: Experience of The Johns Hopkins Health System Regional Emergency Departments. J Am Coll Emerg Physicians Open. 2020 Dec 08;2(1):e12321. doi: 10.1002/emp2.12321. eCollection 2021 Feb. PMID: 33521776; PMCID: PMC7819269.
Copy Download .nbib Format: NLM
[Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.].

Der Radiologe

Scheurlen K, Schnitzer A, Krammer J, Kaiser C, Schönberg SO, Wasser K.
PMID: 24233401
Radiologe. 2013 Nov 15; doi: 10.1007/s00117-013-2572-8. Epub 2013 Nov 15.

PURPOSE: Galactography has been used in cases of pathological discharge for decades. Meanwhile other methods, such as high-resolution ultrasound (US) and magnetic resonance mammography (MRM) have been established for modern multimodal breast imaging. A survey among certified German breast...

Cite
Scheurlen K, Schnitzer A, Krammer J, et al. Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Radiologe. 2013;doi: 10.1007/s00117-013-2572-8.
Scheurlen, K., Schnitzer, A., Krammer, J., Kaiser, C., Schönberg, S. O., & Wasser, K. (2013). Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Der Radiologe, . https://doi.org/10.1007/s00117-013-2572-8
Scheurlen, K, et al. "Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren." [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Der Radiologe vol. (2013). doi: https://doi.org/10.1007/s00117-013-2572-8
Scheurlen K, Schnitzer A, Krammer J, Kaiser C, Schönberg SO, Wasser K. Stellenwert der Galaktographie zur Abklärung pathologischer Sekretion in der komplementären Mammadiagnostik : Teil 1: Eine Onlineumfrage an den deutschen Brustzentren. [Value of galactography for the diagnostic work-up of pathological nipple discharge in multimodal breast diagnostics : Part 1: An online survey among German breast care centers.]. Radiologe. 2013 Nov 15; doi: 10.1007/s00117-013-2572-8. Epub 2013 Nov 15. German. PMID: 24233401.
Copy Download .nbib Format: NLM
Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence.

The Journal of surgical research

O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S.
PMID: 34520983
J Surg Res. 2022 Jan;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11.

BACKGROUND: Colon cancer is a leading cause of cancer-related death. Long non-coding (Lnc) RNAs are critical mediators of tumor biology. H19 is a well-characterized lncRNA involved in p53 regulation and cancer progression. A specific colon cancer data set was...

Cite
O'Brien SJ, Scheurlen K, Rochet A, et al. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2021;269:59-68doi: 10.1016/j.jss.2021.08.004.
O'Brien, S. J., Scheurlen, K., Rochet, A., Fiechter, C., Paas, M., Pan, J., Rai, S. N., & Galandiuk, S. (2022). Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. The Journal of surgical research, 26959-68. https://doi.org/10.1016/j.jss.2021.08.004
O'Brien, Stephen J, et al. "Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence." The Journal of surgical research vol. 269 (2022): 59-68. doi: https://doi.org/10.1016/j.jss.2021.08.004
O'Brien SJ, Scheurlen K, Rochet A, Fiechter C, Paas M, Pan J, Rai SN, Galandiuk S. Increased Expression of Long Non-coding RNA H19 is Associated With Colon Cancer Recurrence. J Surg Res. 2022 Jan;269:59-68. doi: 10.1016/j.jss.2021.08.004. Epub 2021 Sep 11. PMID: 34520983.
Copy Download .nbib Format: NLM
Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma.

Cell death discovery

O'Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Patel A, Rochet A, Scheurlen K, Gardner S, Eichenberger M, Sarojini H, Srivastava S, Rai S, Kalbfleisch T, Polk HC, Galandiuk S.
PMID: 33771981
Cell Death Discov. 2021 Mar 26;7(1):61. doi: 10.1038/s41420-021-00427-x.

Colon adenocarcinoma is a common cause of cancer-related deaths worldwide. Epithelial-mesenchymal transition is a major regulator of cancer metastasis, and increased understanding of this process is essential to improve patient outcomes. Long non-coding RNA (lncRNA) are important regulators of...

Cite
O'Brien SJ, Fiechter C, Burton J, et al. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021;7(1):61doi: 10.1038/s41420-021-00427-x.
O'Brien, S. J., Fiechter, C., Burton, J., Hallion, J., Paas, M., Patel, A., Patel, A., Rochet, A., Scheurlen, K., Gardner, S., Eichenberger, M., Sarojini, H., Srivastava, S., Rai, S., Kalbfleisch, T., Polk, H. C., & Galandiuk, S. (2021). Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell death discovery, 7(1), 61. https://doi.org/10.1038/s41420-021-00427-x
O'Brien, Stephen J, et al. "Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma." Cell death discovery vol. 7,1 (2021): 61. doi: https://doi.org/10.1038/s41420-021-00427-x
O'Brien SJ, Fiechter C, Burton J, Hallion J, Paas M, Patel A, Patel A, Rochet A, Scheurlen K, Gardner S, Eichenberger M, Sarojini H, Srivastava S, Rai S, Kalbfleisch T, Polk HC, Galandiuk S. Long non-coding RNA ZFAS1 is a major regulator of epithelial-mesenchymal transition through miR-200/ZEB1/E-cadherin, vimentin signaling in colon adenocarcinoma. Cell Death Discov. 2021 Mar 26;7(1):61. doi: 10.1038/s41420-021-00427-x. PMID: 33771981; PMCID: PMC7998025.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 12 entries